Startups
We build living human tissue using cells, proteins, and nothing else. Our technology leverages the intersection of personalized medicine, synthetic and computational biology, advanced materials, bioprinting, and AI to go from patient data to human tissue.
Overview
Location
United States, Massachusetts
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 19, 2026 | Carnegie Mellon Leads $28.5M Effort to Create Regenerative Bioprinted Livers | U.S. private research university Carnegie Mellon University has received up to $28.5 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop a 3D bioprinted, immune-compatible liver designed to temporarily support ... |
Reviews 0
FAQ about FluidForm Bio
What has the press written about FluidForm Bio?
Parsers VC has collected 2 articles mentioning FluidForm Bio, among them “Carnegie Mellon Leads $28.5M Effort to Create Regenerative Bioprinted Livers” (Jan 19, 2026).
Is FluidForm Bio still active?
Yes, FluidForm Bio is active; its latest activity on Parsers VC dates from Jan 22, 2026.